Therapeutic Spotlight: Early NSCLC | Physician's Weekly
Advertisement

Therapeutic Spotlight: Early NSCLC

Atezolizumab A Promising Option for Early-Stage NSCLC

In patients with resected stage II-IIIA non-small cell lung cancer (NSCLC), atezolizumab showed a disease-free survival benefit versus best supporting care after adjuvant chemotherapy, with pronounced...

Advertisement

For latest news and updates
Email-id is invalid